ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Holmusk, Veradigm Announce New Phase of Strategic Investment to Fuel Innovation and Close the Evidence Gap in Behavioral Health

Expanded database will enable deeper analysis and insights to enhance care delivery and improve behavioral health outcomes

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, and Holmusk, a leading global behavioral health real-world evidence company, today jointly announced the next stage in its strategic collaboration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231002562008/en/

The collaboration draws on the strengths of each company to fuel innovation in behavioral health and create the evidence needed to move the field forward. In this new phase of the collaboration, cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm will be added to Holmusk’s NeuroBlu Database, a leading source for real-world data that shows how behavioral health care is delivered. Veradigm is also making an additional financial investment in Holmusk, building on a collaboration launched early this year, when Veradigm became the lead investor in Holmusk’s Series B financing round.

“This strategic investment represents significant growth for our NeuroBlu Database, enabling us to move closer to our vision of creating a single source of truth for behavioral health,” said Nawal Roy, Holmusk’s founder and CEO. “This is a crucial step as we work to help eliminate the gaps in evidence, information, and learning that have held the behavioral health industry back from moving to an outcome-based reimbursement system and a learning healthcare system.”

The collaboration expands Holmusk’s NeuroBlu Database by millions of patients. The NeuroBlu Database will now be able to power even more research and address challenging behavioral health questions that require the creation of targeted research cohorts.

“We look forward to taking this next step in our collaboration with Holmusk,” said Rick Poulton, Veradigm’s Chief Executive Officer. “Holmusk’s expertise in preparing clinical real-world data for analysis, including mapping the data to a common data model, will be invaluable in unlocking new insights from our existing resources. We also believe it will enable the creation of much-needed evidence to improve behavioral health outcomes around the world.”

About Holmusk

Holmusk is on a mission to harness real-world data to transform both research and care for behavioral health. Combining the leading behavioral health database with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusk is headquartered in New York, with four additional offices around the world. For more information, please visit www.holmusk.com.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

© 2023 Veradigm Inc. and/or its affiliates. All Rights Reserved.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.76
+0.54 (0.23%)
AAPL  277.90
-0.95 (-0.34%)
AMD  217.66
+0.13 (0.06%)
BAC  53.60
-0.05 (-0.08%)
GOOG  317.45
-2.67 (-0.83%)
META  644.07
-3.88 (-0.60%)
MSFT  487.62
-4.39 (-0.89%)
NVDA  178.71
+1.71 (0.96%)
ORCL  201.76
-0.19 (-0.09%)
TSLA  430.70
+0.53 (0.12%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.